VHL-associated pancreatic neuroendocrine tumors (PNET) afflict 12–17% of VHL patients, and these tumors have been demonstrated to exhibit focal positivity for glucagon [33]. This evidence concerns the gene GCG and primitive neuroectodermal tumor.